Caribou Biosciences IPO

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Total Funding to Date$41.55MM
Register for Details

For more details on financing and valuation for Caribou Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Caribou Biosciences Ticker Symbol


Caribou Biosciences Stock Price

$9.61 as of 12/2/22